SAN DIEGO--(BUSINESS WIRE)--Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that data demonstrating the broad clinical utility and potency of the company’s lead antifungal product candidate, rezafungin, will be presented at IDWeek 2018, being held October 3-7 in San Francisco. Four separate IDWeek presentations will focus on rezafungin, the only once-weekly antifungal product candidate in development for the treatment and prevention of life-threatening invasive fungal infections, and will include the efficacy and safety results from Cidara’s Phase 2 STRIVE trial.
“We look forward to sharing the results of our Phase 2 STRIVE study in an oral presentation at this important meeting,” said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara. “The data we will present at IDWeek support our commitment to advance the development of rezafungin as a potentially novel treatment and prophylactic agent against deadly invasive fungal infections.”
The schedule of IDWeek presentations by Cidara Therapeutics and its collaborators, which comprises one oral and three poster presentations, is as follows:
Title: Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment
Analyses to Support Rezafungin (RZF) Dose Selection in Treatment of
Candida
Date and Time: Friday, October 5, 2018, 12:30 p.m.-1:45
p.m. Pacific Time
Location: S Poster Hall
Poster Presentation
#1390
Session: PK/PD
Studies
Title: Rezafungin Clinical Safety and Efficacy in Patients with
Candidemia and/or Invasive Candidiasis in the Randomized, Double-blind,
Multicenter, Phase 2 STRIVE Study
Date and Time: Saturday, October
6, 2018, 9:30 a.m.-9:45 a.m. Pacific Time
Location: Room S 158
Oral
Presentation #1718
Session: Clinical
Trials that May Change Your Practice
Title: Activity of a Long-Acting Echinocandin, Rezafungin, Tested
against Invasive Fungal Isolates Collected Worldwide
Date and Time:
Saturday, October 6, 2018, 12:30 p.m.-1:45 p.m. Pacific Time
Location:
S Poster Hall
Poster Presentation #2400
Session: Treatment
of AMR Infections
Title: Effect of Rezafungin on QT Interval in Healthy Subjects
Date
and Time: Saturday, October 6, 2018, 12:30 p.m.-1:45 p.m. Pacific Time
Location:
S Poster Hall
Poster Presentation #2389
Session: Treatment
of AMR Infections
Copies of these presentations will be available on the Cidara website following the meeting: www.cidara.com.
About Invasive Fungal Infections
Invasive fungal infections (IFIs) represent a serious threat to millions of patients worldwide, resulting in more than 1.5 million deaths annually and mortality rates ranging from 15 to 65 percent. These infections continue to be a global health issue, especially for critically ill patients in hospitals and patients with compromised immune systems, including cancer and transplant patients. Approximately 90 percent of IFI-related deaths are associated with Candida, Aspergillus, and Pneumocystis.
About Cidara Therapeutics
Cidara is a clinical-stage biotechnology company focused on developing new anti-infectives that have the potential to transform the standard of care and save or improve patients’ lives. The company is currently advancing its novel echinocandin antifungal, rezafungin acetate, formerly known as CD101 IV, through clinical trials. Rezafungin has improved pharmacokinetics compared to existing echinocandins and the potential for expanded utility across patient settings. It is the only once-weekly product candidate in development for the treatment and prevention of life-threatening invasive fungal infections. The company’s Phase 2 STRIVE clinical trial of rezafungin met its primary safety and efficacy objectives, and provides support for Cidara to initiate Phase 3 pivotal trials in the treatment of candidemia and invasive candidiasis and the prophylaxis of invasive fungal infections. Cidara also is leveraging its novel Cloudbreak™ platform to develop antibody-drug conjugates for the treatment of multi-drug resistant Gram-negative bacterial infections. Cloudbreak is the first immunotherapy discovery platform designed specifically to create compounds that directly kill pathogens and also direct a patient’s immune cells to attack and eliminate bacterial, fungal or viral pathogens. Cidara is headquartered in San Diego, California. For more information, please visit www.cidara.com.
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the initiation of rezafungin Phase 3 pivotal trials, the potential for rezafungin to be a novel treatment and prophylactic agent against deadly invasive fungal infections, and rezafungin’s potential for expanded utility across patient settings. Risks that contribute to the uncertain nature of the forward-looking statements include: the success and timing of Cidara’s preclinical studies and clinical trials; regulatory developments in the United States and foreign countries; changes in Cidara’s plans to develop and commercialize its product candidates; Cidara’s ability to obtain additional financing; Cidara’s ability to obtain and maintain intellectual property protection for its product candidates; and the loss of key scientific or management personnel. These and other risks and uncertainties are described more fully in Cidara’s Form 10-Q most recently filed with the United States Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Cidara undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
